Drugs / LINTUZUMAB ACTINIUM AC-225
LINTUZUMAB ACTINIUM AC-225
also known as
Lintuzumab AC 225 · 225 Ac-lintuzumab · 225 Actinium-lintuzumab · 225ac-hum195 · Actimab-a · Actinio (225ac) lintuzumab satetraxetan · Actinium (225ac) lintuzumab satetraxetan · Actinium ac 225 lintuzumab · +4 more
Other / unclassified targets CD33 via depletion
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06802523 | Apr 2026 → Dec 2028 | acute myeloid leukemia | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1 | NCT03441048 | May 2018 → May 2024 | acute myeloid leukemia | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT02998047 | Dec 2016 → May 2020 | plasma cell myeloma | Actinium Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03932318 | Mar → Dec 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03867682 | Jan 2020 → Nov 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02575963 | Oct 2012 → Nov 2018 | acute myeloid leukemia | Actinium Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Actinium Pharmaceuticals | Results Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting actiniumpharma.com ↗
Preclinical translational data demonstrated that lintuzumab-Ac225 delivers potent cytotoxic activity across AML models harboring common mutations, including FLT3, NPM1, KMT2A, and TP53, as well as in primary patient samples. |
| 2023-12-11 | Actinium Pharmaceuticals | Results Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia actiniumpharma.com ↗
Complete responses were achieved including a complete response in a patients with prior Venetoclax treatment and a TP53 mutation |
| 2023-09-07 | Actinium Pharmaceuticals | Results Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO actiniumpharma.com ↗
Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received prior venetoclax treatment |
| 2023-08-31 | Actinium Pharmaceuticals | Results Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting actiniumpharma.com ↗
Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy |
| 2023-04-19 | Actinium Pharmaceuticals | Results Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting actiniumpharma.com ↗
The new data were showcased in a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting, which is being held April 14 - 19, 2023 in Orlando, Florida. |
| 2022-11-03 | Actinium Pharmaceuticals | Results Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial actiniumpharma.com ↗
53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches |
| 2021-11-04 | Actinium Pharmaceuticals | Results Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting actiniumpharma.com ↗
Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study |
| 2020-12-08 | Actinium Pharmaceuticals | Results Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH actiniumpharma.com ↗
One patient who had multiple genetic mutations including IDH2, RUNX1, TP53 and others, achieved a complete remission with incomplete blood count recovery (CRi) after the first cycle of Actimab-A and venetoclax. |
| 2020-12-07 | Actinium Pharmaceuticals | Results Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting actiniumpharma.com ↗
In the third and planned final dose cohort of Actimab-A CLAG-M, 100% of evaluable patients achieved remission. |
| 2020-09-23 | Actinium Pharmaceuticals | Results Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients actiniumpharma.com ↗
All patients from the first dosing cohort (0.50 uCi/kg of Actimab-A) completed treatment and cleared their initial safety evaluation, thus allowing the study to proceed to the second dose cohort of 1.0 uCi/kg Actimab-A added to venetoclax. |
All press releases naming this drug 51 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LINTUZUMAB ACTINIUM AC-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | 225 Ac-lintuzumab | “225 Actinium-lintuzumab (225 Ac-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33” PMID 33347715 ↗ Dec 2020 |
| Known as | 225 Actinium-lintuzumab | “225 Actinium-lintuzumab (225 Ac-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33” PMID 33347715 ↗ Dec 2020 |
| Known as | 225ac-hum195 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Actimab-a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Actinio (225ac) lintuzumab satetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Actinium (225ac) lintuzumab satetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Actinium ac 225 lintuzumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Actinium-225-labeled humanized anti-cd33 monoclonal antibody hum195 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Hum-195 ac-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | Lintuzumab AC 225 | “This phase I trial tests the safety, side effects, and best dose of lintuzumab-Ac225 in combination with venetoclax and ASTX-727, and how well they work in treating patients...” NCT06802523 ↗6“Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.” NCT02998047 ↗ “Drug: Lintuzumab AC 225” NCT02998047 ↗ |
| Known as | Lintuzumab satetraxetan ac-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Known as | SGN-33 AC-225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297554 ↗ |
| Action | Deplete | “highly cytotoxic alpha radiation emitter that targets the cluster of differentiation 33 (CD33) cell surface antigen, which is expressed on leukemic cells” NCT03441048 ↗ |
| Modality | Other / unclassified | “Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.” NCT02998047 ↗ |
| Route | Intravenous | “0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle” NCT02998047 ↗ |
| Target | CD33 | “Lintuzumab attaches to CD33 positive cancer cells” NCT06802523 ↗ |